Nkarta to present initial Phase 1/2 autoimmune data for CAR-NK therapy NKX019 at ACR Convergence 2026

• Nkarta flagged initial Phase 1/2 clinical readouts for CAR-NK therapy NKX019 across autoimmune diseases, with presentations scheduled for ACR Convergence 2026.
• Data will be presented in November in Orlando, covering early signs of clinical activity in idiopathic inflammatory myopathy and systemic sclerosis.
• A separate oral update will outline the overall safety profile across indications, including outcomes tied to the lymphodepletion regimen used before dosing.
• The disclosures mark the first broad public look at NKX019’s autoimmune program, a key near-term catalyst for investor assessment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. nkarta Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080700PRIMZONEFULLFEED9822562) on September 08, 2026, and is solely responsible for the information contained therein.